ANIKA THERAPEUTICS INC (ANIK)
US0352551081 - Common Stock
Overall ANIK gets a fundamental rating of 4 out of 10. We evaluated ANIK against 565 industry peers in the Biotechnology industry. No worries on liquidiy or solvency for ANIK as it has an excellent financial health rating, but there are worries on the profitability. ANIK is valued expensive and it does not seem to be growing.
1. Profitability
1.1 Basic Checks
In the past year ANIK has reported negative net income.
ANIK had a positive operating cash flow in the past year.
The reported net income has been mixed in the past 5 years: ANIK reported negative net income in multiple years.
ANIK had a positive operating cash flow in 4 of the past 5 years.
1.2 Ratios
With a Return On Assets value of -42.14%, ANIK perfoms like the industry average, outperforming 54.45% of the companies in the same industry.
The Return On Equity of ANIK (-54.22%) is better than 64.23% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -42.14% | ||
| ROE | -54.22% | ||
| ROIC | N/A |
ROA(3y)-11.21%
ROA(5y)-6.39%
ROE(3y)-14.24%
ROE(5y)-8.42%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Gross Margin of ANIK (62.70%) is better than 80.25% of its industry peers.
ANIK's Gross Margin has declined in the last couple of years.
The Profit Margin and Operating Margin are not available for ANIK so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 62.7% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y5.37%
GM growth 5Y-2.54%
2. Health
2.1 Basic Checks
ANIK does not have a ROIC to compare to the WACC, probably because it is not profitable.
ANIK has more shares outstanding than it did 1 year ago.
The number of shares outstanding for ANIK has been increased compared to 5 years ago.
There is no outstanding debt for ANIK. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
ANIK has an Altman-Z score of 4.55. This indicates that ANIK is financially healthy and has little risk of bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 4.55, ANIK is in the better half of the industry, outperforming 78.65% of the companies in the same industry.
ANIK has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 4.55 |
ROIC/WACCN/A
WACC10.99%
2.3 Liquidity
A Current Ratio of 5.34 indicates that ANIK has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 5.34, ANIK is in line with its industry, outperforming 56.76% of the companies in the same industry.
A Quick Ratio of 3.78 indicates that ANIK has no problem at all paying its short term obligations.
Looking at the Quick ratio, with a value of 3.78, ANIK is in line with its industry, outperforming 46.62% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 5.34 | ||
| Quick Ratio | 3.78 |
3. Growth
3.1 Past
The earnings per share for ANIK have decreased strongly by -235.86% in the last year.
Looking at the last year, ANIK shows a small growth in Revenue. The Revenue has grown by 0.53% in the last year.
ANIK shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 9.56% yearly.
EPS 1Y (TTM)-235.86%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%44.44%
Revenue 1Y (TTM)0.53%
Revenue growth 3Y8.49%
Revenue growth 5Y9.56%
Sales Q2Q%-6.54%
3.2 Future
Based on estimates for the next years, ANIK will show a quite strong growth in Earnings Per Share. The EPS will grow by 17.81% on average per year.
Based on estimates for the next years, ANIK will show a small growth in Revenue. The Revenue will grow by 7.34% on average per year.
EPS Next Y50.41%
EPS Next 2Y40.08%
EPS Next 3Y27.36%
EPS Next 5Y17.81%
Revenue Next Year-9.03%
Revenue Next 2Y-16.72%
Revenue Next 3Y-9.04%
Revenue Next 5Y7.34%
3.3 Evolution
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
ANIK reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ANIK. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of ANIK indicates a rather cheap valuation: ANIK is cheaper than 94.13% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | 47.49 |
4.3 Compensation for Growth
ANIK's earnings are expected to grow with 27.36% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y40.08%
EPS Next 3Y27.36%
5. Dividend
5.1 Amount
No dividends for ANIK!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
ANIKA THERAPEUTICS INC
NASDAQ:ANIK (12/24/2024, 7:55:28 PM)
16.33
+0.1 (+0.62%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners92.08%
Inst Owner Change-1.04%
Ins Owners2.85%
Ins Owner Change2.98%
Market Cap239.23M
Analysts87.5
Price Target27.03 (65.52%)
Short Float %2.6%
Short Ratio3.59
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-827.5%
Min EPS beat(2)-1533.99%
Max EPS beat(2)-121.01%
EPS beat(4)0
Avg EPS beat(4)-804.68%
Min EPS beat(4)-1533.99%
Max EPS beat(4)-62.81%
EPS beat(8)1
Avg EPS beat(8)-412.3%
EPS beat(12)4
Avg EPS beat(12)-271.06%
EPS beat(16)7
Avg EPS beat(16)-155.77%
Revenue beat(2)0
Avg Revenue beat(2)-6.05%
Min Revenue beat(2)-9.72%
Max Revenue beat(2)-2.38%
Revenue beat(4)2
Avg Revenue beat(4)-2.21%
Min Revenue beat(4)-9.72%
Max Revenue beat(4)1.75%
Revenue beat(8)5
Avg Revenue beat(8)0.9%
Revenue beat(12)9
Avg Revenue beat(12)2.82%
Revenue beat(16)12
Avg Revenue beat(16)3.07%
PT rev (1m)-23.19%
PT rev (3m)-17.19%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-400%
EPS NY rev (1m)0%
EPS NY rev (3m)-1152.38%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-15.43%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-11.76%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 1.46 | ||
| P/FCF | N/A | ||
| P/OCF | 32.06 | ||
| P/B | 1.33 | ||
| P/tB | 1.41 | ||
| EV/EBITDA | 47.49 |
EPS(TTM)-4.87
EYN/A
EPS(NY)-0.2
Fwd EYN/A
FCF(TTM)-0.1
FCFYN/A
OCF(TTM)0.51
OCFY3.12%
SpS11.21
BVpS12.28
TBVpS11.54
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -42.14% | ||
| ROE | -54.22% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 62.7% | ||
| FCFM | N/A |
ROA(3y)-11.21%
ROA(5y)-6.39%
ROE(3y)-14.24%
ROE(5y)-8.42%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y5.37%
GM growth 5Y-2.54%
F-Score6
Asset Turnover0.71
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | 0 | ||
| Cap/Depr | 89.75% | ||
| Cap/Sales | 5.4% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | 200.4% | ||
| Profit Quality | N/A | ||
| Current Ratio | 5.34 | ||
| Quick Ratio | 3.78 | ||
| Altman-Z | 4.55 |
F-Score6
WACC10.99%
ROIC/WACCN/A
Cap/Depr(3y)41.93%
Cap/Depr(5y)37.03%
Cap/Sales(3y)3.84%
Cap/Sales(5y)3.05%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-235.86%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%44.44%
EPS Next Y50.41%
EPS Next 2Y40.08%
EPS Next 3Y27.36%
EPS Next 5Y17.81%
Revenue 1Y (TTM)0.53%
Revenue growth 3Y8.49%
Revenue growth 5Y9.56%
Sales Q2Q%-6.54%
Revenue Next Year-9.03%
Revenue Next 2Y-16.72%
Revenue Next 3Y-9.04%
Revenue Next 5Y7.34%
EBIT growth 1Y74.62%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year157.51%
EBIT Next 3Y36.1%
EBIT Next 5Y29.95%
FCF growth 1Y-160.39%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-11.15%
OCF growth 3YN/A
OCF growth 5YN/A